Human papillomavirus 16 E6/E7 contributes to immune escape and progression of cervical cancer by regulating miR-142-5p/PD-L1 axis

被引:14
|
作者
Ling, Junjun [1 ]
Sun, Qinghua [1 ]
Tian, Qin [1 ]
Shi, Huaxin [1 ]
Yang, Hui [1 ]
Ren, Jie [1 ]
机构
[1] Guizhou Med Univ, Affiliated Hosp, Guiyang 550004, Peoples R China
关键词
Cervical carcinoma; MicroRNA; PD-L1; Immune escape; METASTASIS;
D O I
10.1016/j.abb.2022.109449
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Persistent infection of human papillomavirus (HPV) and immune escape are the main causes of cervical cancer. E6/E7 encoded by HPV16 may be closely related to carcinogenesis. HPV infection may upregulate PD-L1 expression, resulting in immune escape and cervical cancerigenesis. Evidence indicates that miRNAs may mediate the regulation of E6/E7 on PD-L1. Therefore, we aimed to screen the miRNA, and further verify its expression and functions. Bioinformatics approaches were used to screen the miRNAs that mediate the regulation of E6/E7 on PD-L1. The expression of the miRNA and PD-L1 in HPV+ and HPV- cervical cancer cells were compared, and the effect of E6E7 on them was evaluated. Then, the effect of the miRNA on PD-L1 was assessed by the Gain-and Loss-of-function test. Finally, in vivo experiments were conducted to verify the effects of the miRNA on tumor growth and survival of tumor-bearing mice. Six miRNAs were screened, of which miR-142-5p was identified. MiR-142-5p was downregulated and PD-L1 was upregulated in HPV- cells after transfection of E6, E7, or E6/E7. The rescue test showed that the upregulation of miR-142-5p attenuated the effect of E6/E7 on PD-L1. The reverse relationship between PD-L1 and miR-142-5p was confirmed. In vivo experiments suggest that miR-142-5p upregulation inhibits the growth of the transplanted tumors by targeting PD-L1. MiR-142-5p acts as a tumor suppressor in cervical cancer. HPV16 E6E7 may promote the immune escape of cervical cancer cells by regulating the miR-142-5p/PD-L1 axis. Using miR-142-5p in tumor immunotherapy as a new strategy is proposed.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Human papillomavirus type 16 E6 and E7 gene variations associated with cervical cancer in a Han Chinese population
    Zhou, Ziyun
    Yang, Hongying
    Yang, Lijuan
    Yao, Yueting
    Dai, Shuying
    Shi, Li
    Li, Chuanyin
    Yang, Longyu
    Yan, Zhiling
    Yao, Yufeng
    INFECTION GENETICS AND EVOLUTION, 2019, 73 : 13 - 20
  • [22] Frequency of E6 and E7 Oncogenes of Human Papillomavirus Types 16 and 18 in Cervical Cancer Patients in Pakistani Women
    Zahid, Aliya
    Shakoon, A. R.
    PAKISTAN JOURNAL OF ZOOLOGY, 2016, 48 (06) : 1911 - 1917
  • [23] Genetic variability in E6 and E7 oncogenes of human papillomavirus Type 16 from Congolese cervical cancer isolates
    Luc Magloire Anicet Boumba
    Samira Zoa Assoumou
    Lahoucine Hilali
    Jean Victor Mambou
    Donatien Moukassa
    Mustapha Moulay Ennaji
    Infectious Agents and Cancer, 10
  • [24] CONSERVATION OF E6 AND E7 REGIONS OF HUMAN PAPILLOMAVIRUS TYPES 16 AND 18 PRESENT IN CERVICAL CANCERS
    TAKEBE, N
    TSUNOKAWA, Y
    NOZAWA, S
    TERADA, M
    SUGIMURA, T
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 143 (03) : 837 - 844
  • [25] Inhibition of apoptosis in human laryngeal cancer cells by E6 and E7 oncoproteins of human papillomavirus 16
    Liu, Han Ching
    Chen, George G.
    Vlantis, Alexander C.
    Tse, Gary M.
    Chan, Anthony T. C.
    van Hasselt, C. Andrew
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2008, 103 (04) : 1125 - 1143
  • [26] Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells
    Sima, Ni
    Wang, Shixuan
    Wang, Wei
    Kong, Debo
    Xu, Qian
    Tian, Xu
    Luo, Aiyue
    Zhou, Jianfeng
    Xu, Gang
    Meng, Li
    Lu, Yunping
    Ma, Ding
    GYNECOLOGIC ONCOLOGY, 2007, 106 (02) : 299 - 304
  • [27] Human Papillomavirus 16 E6/E7 Transcript and E2 Gene Status in Patients with Cervical Neoplasia
    Narayanan Sathish
    Priya Abraham
    Abraham Peedicayil
    Gopalan Sridharan
    Subhashini John
    George Chandy
    Molecular Diagnosis, 2004, 8 (1) : 57 - 64
  • [28] HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway
    Konstantopoulos, Georgios
    Leventakou, Danai
    Saltiel, Despoina-Rozi
    Zervoudi, Efthalia
    Logotheti, Eirini
    Pettas, Spyros
    Karagianni, Korina
    Daiou, Angeliki
    Hatzistergos, Konstantinos E.
    Dafou, Dimitra
    Arsenakis, Minas
    Kottaridi, Christine
    VIRUSES-BASEL, 2024, 16 (01):
  • [29] A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
    Borysiewicz, LK
    Fiander, A
    Nimako, M
    Man, S
    Wilkinson, GWG
    Westmoreland, D
    Evans, AS
    Adams, M
    Stacey, SN
    Boursnell, MEG
    Rutherford, E
    Hickling, JK
    Inglis, SC
    LANCET, 1996, 347 (9014): : 1523 - 1527
  • [30] Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations
    Nindl, I
    Zumbach, K
    Pawlita, M
    Teller, K
    Schneider, A
    Dürst, M
    JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (05): : 1764 - 1767